Australia: Death of the starting point approach under the Patents Act: AstraZeneca v Apotex

Last Updated: 31 October 2014
Article by Katrina Crooks and Wen Wu

A recent decision of the Full Court of the Federal Court of Australia, AstraZeneca AB v Apotex Pty Ltd (2014) 312 ALR 1 ('AstraZeneca') has clarified the tests for novelty and inventive step under the Patents Act 1990 (Cth).

In relation to inventive step, the Full Court in AstraZeneca marked its disapproval of the 'starting point' approach previously adopted by an earlier Full Court. Instead, the Full Court emphasised the objective nature of the test, namely, a comparison between the invention as claimed and common general knowledge, considered alone or together with relevant prior art information.

As regards novelty, the Full Court held that, while common general knowledge may be used to construe a prior art document, it is not permissible to add common general knowledge to the document when comparing the prior art with the claimed invention.


AstraZeneca appealed to the Full Court from the trial judge's decision in Apotex v AstraZeneca (No 4). At first instance AstraZeneca's patents were held to be invalid on a number of grounds, including novelty and inventive step. The appeal concerned two patents, AU 200023051 (''051 Patent') and AU 200051842 (''842 Patent'). The '051 Patent claimed methods of treating a patient suffering from hypercholesterolemia comprising administration of a particular dosage of the pharmaceutical compound, rosuvastatin. The '842 Patent claimed pharmaceutical compositions comprising rosuvastatin and an inorganic salt.

Inventive step and the 'starting point' approach

One of the issues which the Full Court was required to consider in the assessment of inventive step was the so-called 'starting point' approach: does an invention involve an inventive step where the invention is an obvious solution to a problem, but the problem is not common general knowledge nor known in the relevant prior art? The 'starting point' approach had previously been adopted by the Full Court in Apotex v Sanofi-Aventis [2009] FCAFC 134 ('Sanofi'), and has particular application in cases where the patent specification outlines a particular problem (and sets out to solve that problem), but where that problem is not necessarily common general knowledge in the relevant field. In Sanofi, the Full Court analysed the inventive concept of the patent by reference to the specification, and specifically the identification of the problem which the patent set out to solve. It then considered whether that inventive concept was obvious in light of the relevant prior art information.

In the context of assessing inventive step for the rosuvastatin patents, the specific question was whether the compound rosuvastatin and its properties should be treated as the "starting point", since such knowledge of rosuvastatin was acknowledged in the relevant patent specifications (but was not found to be common general knowledge at the relevant dates). If so, AstraZeneca would need to show that the particular method of treatment and compositions claimed were inventive when considered in light of knowledge of the rosuvastatin compound. However if the starting point did not include knowledge of rosuvastatin it would be much easier for AstraZeneca to establish inventiveness.

The generic parties also argued that even adhering strictly to subsection 7(2) as the "starting point", a correct interpretation of that subsection allows for comparison of the invention with any publically available information (as defined in the Patents Act as the "prior art base"), and is not limited to a comparison with the common general knowledge and the information defined in subsection 7(3) ('prior art information'), which is importantly limited by the requirement that it be information which the skilled person could be reasonably expected to have ascertained, understood, regarded as relevant. This requirement will commonly exclude patent specifications from subsection 7(3), given that skilled persons in many areas of technology might not be expected to consult such documents in the course of innovation.

A four-judge majority of the Full Court held:

  • Subsection 7(2) of the Patents Act requires inventive step to be assessed by reference to common general knowledge, considered separately or together with the relevant prior art information in subsection 7(3). The argument for a wider reading of subsection 7(2) was rejected;
  • The body of knowledge and information against which inventive step is assessed cannot be enlarged by reference to the description of the invention in the patent specification, including description of any problem that the invention is directed at solving;
  • If a problem described in the specification is common general knowledge or prior art information, then awareness of the problem will be attributed to the skilled addressee. However, where the problem is not common general knowledge or s.7(3) information, then the description in the specification cannot be used to attribute awareness of the problem to the skilled addressee;
  • Therefore, the 'starting point' approach adopted in Sanofi should not be applied to the assessment of inventive step under the Patents Act 1990.

In the result, the Full Court upheld the trial judge's conclusion that the '051 Patent was obvious, even taking the more general starting point. Because the majority held that the '842 Patent lacked novelty, it was not necessary to decide whether it also lacked inventive step. However, the majority of the Court indicated that if the '842 Patent were novel, it would have allowed AstraZeneca's appeal on inventive step because the trial judge erroneously treated knowledge of rosuvastatin as a given starting point.

Novelty and the use of common general knowledge

The Full Court also upheld AstraZeneca's appeal that the trial judge erred in assessing novelty of the '051 Patent by reading common general knowledge into a prior art document (Watanabe).

Although common general knowledge may be used to construe a prior art document, the Full Court held that it is not permissible to add common general knowledge to the document to result in information which the prior art document alone does not disclose.

As a result, the Full Court found the '051 Patent novel. However, because it dismissed AstraZeneca's appeals on inventive step and entitlement, the order to revoke the '051 Patent was not disturbed.

Implications for patent validity going forward

In some cases, the Full Court's rejection of the starting point approach is likely to make it significantly more difficult for would-be opponents to patents to establish invalidity on the grounds of obviousness. This will particularly be so, where the patentee/patent applicant is aware of previous technology which is not in the common general knowledge. In such cases, even where such prior art is identified in the patent specification, it cannot be taken into account unless it is shown to be prior art information. Where the technology is described in an earlier patent specification, there may be difficulties, at least in some fields, in showing that the patent would have been ascertained by a person skilled in art, so as to be treated as prior art information. In those cases, it seems that a person may be able to obtain a patent for making an obvious addition to existing technology of which that person was aware.

On the other hand, the Full Court's approach removes potential subjectivities introduced by the starting point approach. The Full Court noted that using a starting point approach would mean that an invention could be obvious if made by one inventor who was aware of certain relevant information (and took it upon themselves to include this information in the patent specification), but not obvious if made by another, who was not aware of such information.

The question as to the appropriate interpretation of section 7(2), and whether the invention should be compared to the "prior art base" as defined or only the common general knowledge together with relevant prior art information within section 7(3) is an interesting one. As the Full Court made clear, the High Court has taken the narrower interpretation on several occasions and the Full Court was bound by that interpretation. Nevertheless, the web of references created by subsections 7(2) and (3) and the definitions of "prior art base" and "prior art information" in the Patents Act 1990 do not inevitably lead to an obvious answer. To some extent these difficulties may be overcome by the Raising the Bar amendments which remove the requirement that relevant prior art information could reasonably have been ascertained, understood and regarded as relevant, bringing section 7(3) closer to the prior art base. However the way in which section 7(3) will be interpreted post-Raising the Bar has not yet been tested and this may raise some questions of its ownll.

In the meantime, the importance of analysing obviousness arguments in a very detailed manner, particularly before embarking on evidence preparation cannot be overemphasised. As Rosuvastatin shows us, getting the right starting point can be crucial.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Shelston IP has been awarded the MIP Global Award for Australian IP Firm of the Year 2013.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Katrina Crooks
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.